0 111

Cited 0 times in

Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

Authors
 Hye Won Lee  ;  Jun Yong Park  ;  Taegon Hong  ;  Min Soo Park  ;  Sang Hoon Ahn 
Citation
 Clin Gastroenterol Hepatol, : epub., 2019 
Journal Title
 Clin Gastroenterol Hepatol 
Issue Date
2019
Abstract
The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti-HB-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2-4.
Full Text
https://www.sciencedirect.com/science/article/pii/S1542356519310894
DOI
10.1016/j.cgh.2019.09.038
Appears in Collections:
7. Others (기타) > Others (기타) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
Yonsei Authors
Park, Min Soo(박민수) ORCID logo https://orcid.org/0000-0002-4395-9938
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Lee, Hye Won(이혜원) ORCID logo https://orcid.org/0000-0002-3552-3560
Hong, Tae Gon(홍태곤) ORCID logo https://orcid.org/0000-0001-7490-0085
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/175751
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse